ArticleClinical colorectal cancer2019
A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer.
Charalampos S Floudas et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
32 papers cite it
this papercites it